- Conditions
- Influenza, Human
- Interventions
- KT07 Capsule, Placebo
- Drug · Other
- Lead sponsor
- Yiling Pharmaceutical Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Tolleson, Arizona + 66 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,138
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dysexecutive Syndrome, Post-Acute Sequelae of COVID-19
- Interventions
- Active tDCS, Sham tDCS
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- Stroke, Acute
- Interventions
- Telestroke
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Edina, Minnesota
- Conditions
- COVID-19
- Interventions
- Convalescent plasma, Placebo
- Biological
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- cytarabine, deoxycytidine
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Corona Virus Infection, Pediatric Cancer, Adult Children, Cancer
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 24 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, double-unit umbilical cord blood transplantation, total-body irradiation, tacrolimus, peripheral blood stem cell transplantation
- Drug · Procedure · Radiation
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Post-acute COVID-19 Syndrome
- Interventions
- Xltranplus, Xltran
- Other
- Lead sponsor
- LUCINDA BATEMAN, MD
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- HIV Infections
- Interventions
- darunavir 800 mg, FTC 200 mg/TDF 300mg, Maraviroc, Raltegravir, Ritonavir 100 mg
- Drug
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Severe Acute Respiratory Syndrome
- Interventions
- Otilimab, Placebo 1, Placebo 2, Standard of care
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 21
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more
- Conditions
- Long COVID
- Interventions
- N-803 (IL-15 Superagonist)
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- Cyclophosphamide, Psoralen, Thiotepa, Allogeneic bone marrow transplantation, In vitro-treated peripheral blood stem cell transplantation (PBSCT), Radiation Therapy (RT)
- Drug · Procedure · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 49 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • St Louis, Missouri • Houston, Texas
- Conditions
- Viral Infection, Acute Respiratory Infection, Upper Resp Tract Infection
- Interventions
- BioFire® Respiratory Panel 2.1-EZ
- Diagnostic Test
- Lead sponsor
- Andrew Meltzer
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
- Interventions
- Rosuvastatin (crestor), Placebo
- Drug
- Lead sponsor
- Gordon Bernard
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 21
- States / cities
- Little Rock, Alaska • Phoenix, Arizona • Stanford, California + 17 more
- Conditions
- Patient Compliance, Medication Adherence, Medication Non-Adherence
- Interventions
- Information prescriptions
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,940 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Columbia, Maryland
- Conditions
- Long COVID, Long Covid19, Long Covid-19
- Interventions
- Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care
- Behavioral · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
- Conditions
- COVID-19, Post Acute Sequelae of COVID-19, Long COVID, Organ Dysfunction Syndrome, Multiple, Frailty Syndrome
- Interventions
- Blood and nasal swab sampling
- Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Sylmar, California • Torrance, California + 3 more
- Conditions
- Prone Positioning, High Flow Nasal Cannula, Acute Respiratory Distress Syndrome, Corona Virus Infection
- Interventions
- high flow nasal cannula (HFNC), Prone positioning (PP)
- Device · Procedure
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pyroxamide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Long COVID Symptoms
- Interventions
- Sonocea Sonic Augmentation Technology (SAT), Truvaga Electrical Vagus Nerve Stimulator
- Other
- Lead sponsor
- Leidos Life Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 546 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Frederick, Maryland
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Inotuzumab ozogamicin, Methotrexate, Hydrocortisone, Cytarabine, Diphenhydramine, Acetaminophen, Methylprednisolone
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 2
- States / cities
- San Diego, California • Memphis, Tennessee
- Conditions
- Cytomegalovirus Infections
- Interventions
- valganciclovir, Placebo
- Drug · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Covid19
- Interventions
- Not listed
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 6 Months to 120 Years
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- alemtuzumab, therapeutic allogeneic lymphocytes, fludarabine phosphate, melphalan, tacrolimus, thiotepa, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut